GSE179235 MEK NRAS inhibition 0 v 6 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE179235_MEK_NRAS inhibition_0_v_6_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE179235_MEK_NRAS inhibition_0_v_6_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE179235_MEK_NRAS inhibition_0_v_6_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE179235_MEK_NRAS inhibition_0_v_6_human_up.

Results found

Linked to

 

Label

Description

 

Gene

synergin gamma

Gene

tripartite motif containing 16 like (pseudogene)

Gene

long intergenic non-protein coding RNA 205

Gene

POU class 3 homeobox 3

Gene

long intergenic non-protein coding RNA 511

Gene

cutA divalent cation tolerance like, pseudogene

Gene

BAIAP2 divergent transcript

Gene

metastasis associated lung adenocarcinoma transcript 1

Gene

TP53 target 1

Gene

DPPA2 upstream binding RNA


  • Gene

    tripartite motif containing 16 like (pseudogene)


  • Gene

    long intergenic non-protein coding RNA 205


  • Gene

    POU class 3 homeobox 3


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    cutA divalent cation tolerance like, pseudogene


  • Gene

    BAIAP2 divergent transcript


  • Gene

    metastasis associated lung adenocarcinoma transcript 1



  • Gene

    DPPA2 upstream binding RNA

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.